Art. -Nr.: HY-15355

Loviride

(Synonyms: R 89439)

Kundenbewertung

Based on 1 Customer Validation

Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), with an IC₅₀ of 0.3 µM for reverse transcriptase from HIV-1. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.59%
CAS. Nr.: 147362-57-0
Formel: C₁₇H₁₆Cl₂N₂O₂
Molecular Weight:351.23

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Loviride Chemical Structure

CAS. Nr.: 147362-57-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

HIV-1

HIV-2

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
MT4	CC₅₀	137 μM Compound: Loviride	Cytotoxic concentration based on the reduction of viability of mock-infected cells Cytotoxic concentration based on the reduction of viability of mock-infected cells	[PMID: 7540208]
MT4	EC₅₀	0.006 μM Compound: Loviride	Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells	[PMID: 7540208]
MT4	EC₅₀	0.013 μM Compound: 5	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.05 μM Compound: 5	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	1.3 μM Compound: 5	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	13 nM Compound: 47	Antiviral activity against Human immunodeficiency virus 1 infected in human MT4 cells Antiviral activity against Human immunodeficiency virus 1 infected in human MT4 cells	[PMID: 19632850]
MT4	EC₅₀	16 μM Compound: 5	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	50 μM Compound: 5	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	IC₅₀	>10 μM Compound: R-89439	Concentration required to inhibit the viral (HIV-1 NNRTI resistant strain) cytopathic effect by 50% in MT-4 cells. Concentration required to inhibit the viral (HIV-1 NNRTI resistant strain) cytopathic effect by 50% in MT-4 cells.	[PMID: 12672256]
MT4	IC₅₀	>10 μM Compound: R-89439	Concentration required to inhibit the viral (HIV-2 ROD) cytopathic effect by 50% in MT-4 cells. Concentration required to inhibit the viral (HIV-2 ROD) cytopathic effect by 50% in MT-4 cells.	[PMID: 12672256]
MT4	IC₅₀	>10 μM Compound: R-89439	Concentration required to inhibit the viral (SIV mac251) cytopathic effect by 50% in MT-4 cells. Concentration required to inhibit the viral (SIV mac251) cytopathic effect by 50% in MT-4 cells.	[PMID: 12672256]
MT4	IC₅₀	>10 μM Compound: R-89439	Concentration that reduced the MT-4 cell viability by 50%. Concentration that reduced the MT-4 cell viability by 50%.	[PMID: 12672256]
MT4	IC₅₀	0.006 μM Compound: R-89439	Concentration required to inhibit the viral (HIV-1 NL4.3 strain) cytopathic effect by 50% in MT-4 cells. Concentration required to inhibit the viral (HIV-1 NL4.3 strain) cytopathic effect by 50% in MT-4 cells.	[PMID: 12672256]
MT4	IC₅₀	0.014 μM Compound: R-89439	Concentration required to inhibit the viral (HIV-1 IIIB strain) cytopathic effect by 50% in MT-4 cells. Concentration required to inhibit the viral (HIV-1 IIIB strain) cytopathic effect by 50% in MT-4 cells.	[PMID: 12672256]
MT4	IC₅₀	0.05 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	0.05 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	0.063 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	1 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	1.26 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	13 nM Compound: 7	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22268494]
MT4	IC₅₀	15.8 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	2.51 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	50.1 μM Compound: Loviride	Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus	[PMID: 11527703]

In Vitro

Loviride (0.01 µM) inhibits HIV-1(IIIB) replication in MT-4 cells, also inhibits HIV-2 and SIV, with EC₅₀s of 85.5, 7.4 µM for HIV-2 (ROD), HIV-2 (EHO), and 11.4, 28.5, 57.0 µM for SIV (mac251), SIV (agm3), SIV (mndGB1), respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 147362-57-0
Appearance Solid
Molecular Weight 351.23
Formel C₁₇H₁₆Cl₂N₂O₂
Color Light yellow to yellow
SMILES

O=C(N)C(NC1=C(C(C)=O)C=CC(C)=C1)C2=C(Cl)C=CC=C2Cl
Synonyms

R 89439
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 62.5 mg/mL (177.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8471 mL

14.2357 mL

28.4714 mL

5 mM

0.5694 mL

2.8471 mL

5.6943 mL

10 mM

0.2847 mL

1.4236 mL

2.8471 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 6.25 mg/mL (17.79 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Witvrouw M, et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999 Aug 20;13(12):1477-83. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8471 mL	14.2357 mL	28.4714 mL	71.1784 mL
	5 mM	0.5694 mL	2.8471 mL	5.6943 mL	14.2357 mL
	10 mM	0.2847 mL	1.4236 mL	2.8471 mL	7.1178 mL
	15 mM	0.1898 mL	0.9490 mL	1.8981 mL	4.7452 mL
	20 mM	0.1424 mL	0.7118 mL	1.4236 mL	3.5589 mL
	25 mM	0.1139 mL	0.5694 mL	1.1389 mL	2.8471 mL
	30 mM	0.0949 mL	0.4745 mL	0.9490 mL	2.3726 mL
	40 mM	0.0712 mL	0.3559 mL	0.7118 mL	1.7795 mL
	50 mM	0.0569 mL	0.2847 mL	0.5694 mL	1.4236 mL
	60 mM	0.0475 mL	0.2373 mL	0.4745 mL	1.1863 mL
	80 mM	0.0356 mL	0.1779 mL	0.3559 mL	0.8897 mL
	100 mM	0.0285 mL	0.1424 mL	0.2847 mL	0.7118 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Loviride

Human Metabolite Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Loviride

Human Metabolite Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Loviride Related Classifications

HY-15355 Related Classifications